You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

transformed SCLC, EGFR-mutated NSCLC

Showing 1 - 25 of 5,530
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Small-cell Lung Cancer Trial in Guangzhou (Serplulimab)

Recruiting
  • Small-cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial Perople's Hospital
Jul 20, 2023

EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine Trial run by the National Cancer Institute (NCI)

Recruiting
  • EGFR-Mutated Non-Small-Cell Lung Carcinoma
  • Small Cell/Neuroendocrine
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)

Not yet recruiting
  • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
  • (no location specified)
Aug 27, 2023

Brain Metastases, Radiotherapy, EGFR Activating Mutation Trial in Guangdong (brain radiotherapy, Almonertinib)

Recruiting
  • Brain Metastases
  • +2 more
  • Guangdong, Guangzhou, China
    Sun-Yat-Sen university
Mar 13, 2023

Non Small Cell Lung Cancer Trial in Hangzhou (Furmonertinib Mesilate Tablets)

Enrolling by invitation
  • Non Small Cell Lung Cancer
  • Furmonertinib Mesilate Tablets
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Apr 3, 2023

NSCLC Trial in Beijing (RC108)

Not yet recruiting
  • NSCLC
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Apr 18, 2023

NSCLC Trial (Amivantamab, Lazertinib, Doxycycline)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Nov 7, 2023

NSCLC Trial in Chongqing (Aumonertinib 165mg orally once daily and intrathecal chemo with pemetrexed)

Recruiting
  • Non-small Cell Lung Cancer
  • Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed
  • Chongqing, China
    chongqing University Three Gorges Hospital
Apr 11, 2023

NSCLC Trial in Santa Rosa, Ridgewood (Tipifarnib, Osimertinib)

Recruiting
  • NSCLC
  • Santa Rosa, California
  • +1 more
Jan 11, 2023

NSCLC, EGFR Activating Mutation, Brain Metastases Trial in Beijing (TY-9591, Osimertinib)

Not yet recruiting
  • NSCLC
  • +2 more
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospitial,Chinese Academy of Medic
Jul 9, 2023

Metastatic Non Small Cell Lung Cancer Trial in Australia, Singapore (Osimertinib, Stereotactic Radiosurgery (SRS))

Recruiting
  • Metastatic Non Small Cell Lung Cancer
  • Newcastle, New South Wales, Australia
  • +12 more
Nov 16, 2022

Lung Adenocarcinoma, Lung Tumors Trial run by the NCI (osimertinib, LAT)

Completed
  • Lung Adenocarcinoma
  • Lung Neoplasms
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Oct 17, 2022

PD-1 Blockade Plus Platinum-based Chemotherapy in EGFR Sensitive

Completed
  • Non Small Cell Lung Cancer
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Mar 9, 2022

    NSCLC Trial in Xi'an (Furmonertinib+cisplating/pemetrexed)

    Recruiting
    • Non-small Cell Lung Cancer
    • Xi'an, Shannxi, China
      Tangdu Hospital
    Jun 20, 2022

    NSCLC (NSCLC) Trial in Japan, United States (Patritumab deruxtecan, Osimertinib)

    Recruiting
    • Non-Small Cell Lung Cancer (NSCLC)
    • Santa Monica, California
    • +13 more
    Feb 1, 2023

    NSCLC, EGFR Activating Mutation, Brain Metastases Trial in Beijing (TY-9591 Tablets)

    Recruiting
    • NSCLC
    • +3 more
    • TY-9591 Tablets
    • Beijing, Beijing, China
      National Cancer Center/Cancer Hospitial,Chinese Academy of Medic
    May 14, 2022

    Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 Trial in

    Recruiting
    • Advanced Lung Non-Small Cell Carcinoma
    • +9 more
    • Biopsy
    • +2 more
    • Duarte, California
      City of Hope Medical Center
    Aug 2, 2022

    Non Small Cell Lung Cancer Trial in Shanghai (Tislelizumab, Carboplatin, Pemetrexed)

    Recruiting
    • Non Small Cell Lung Cancer
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Nov 19, 2021

    NSCLC Trial in Shanghai (Pembrolizumab, Lenvatinib)

    Recruiting
    • NSCLC
    • Shanghai, China
      Department of Oncology, Shanghai Lung Cancer Center, Shanghai Ch
    Dec 7, 2021

    NSCLC, EGF-R Positive NSCLC Trial in Shenyang (Icotinib, Cisplatin, Carboplatin)

    Not yet recruiting
    • NSCLC
    • EGF-R Positive Non-Small Cell Lung Cancer
    • Shenyang, Liaoning, China
      Liaoning Cancer Hospital & Institute
    Nov 28, 2021

    NSCLC, EGFR Gene Mutation, EGF-R Positive NSCLC Trial in Jerusalem (Stereotactic surgery)

    Recruiting
    • NSCLC
    • +4 more
    • Stereotactic surgery
    • Jerusalem, Israel
      Hadassah Ein Kerem Medical Center
    Aug 30, 2021

    Lung Cancer Trial in Guangzhou (Osimertinib, Bevacizumab)

    Not yet recruiting
    • Lung Cancer
    • Guangzhou, Guangdong, China
      Guangdong Provincial People's Hospital
    Jul 26, 2021

    Lung Cancer Stage II Trial (Camrelizumab+ pemetrexed + platinum)

    Not yet recruiting
    • Lung Cancer Stage II
    • Camrelizumab+ pemetrexed + platinum
    • (no location specified)
    Jul 16, 2021

    Osimertinib for HK Chinese With Metastatic T790M Mutated

    Completed
    • Non-small Cell Lung Cancer
    • Hong Kong, China
    • +3 more
    Sep 7, 2021

    NSCLC Trial (Recombinant anti-VEGFR2 fully human mAb (JY025))

    Not yet recruiting
    • NSCLC
    • Recombinant anti-VEGFR2 fully human monoclonal antibody (JY025)
    • (no location specified)
    May 7, 2021